252 related articles for article (PubMed ID: 32276429)
1. Electrophysiological Abnormalities in VLCAD Deficient hiPSC-Cardiomyocytes Can Be Improved by Lowering Accumulation of Fatty Acid Oxidation Intermediates.
Knottnerus SJG; Mengarelli I; Wüst RCI; Baartscheer A; Bleeker JC; Coronel R; Ferdinandusse S; Guan K; IJlst L; Li W; Luo X; Portero VM; Ulbricht Y; Visser G; Wanders RJA; Wijburg FA; Verkerk AO; Houtkooper RH; Bezzina CR
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32276429
[TBL] [Abstract][Full Text] [Related]
2. Electrophysiological Abnormalities in VLCAD Deficient hiPSC-Cardiomyocytes Do not Improve with Carnitine Supplementation.
Verkerk AO; Knottnerus SJG; Portero V; Bleeker JC; Ferdinandusse S; Guan K; IJlst L; Visser G; Wanders RJA; Wijburg FA; Bezzina CR; Mengarelli I; Houtkooper RH
Front Pharmacol; 2020; 11():616834. PubMed ID: 33597881
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid oxidation flux predicts the clinical severity of VLCAD deficiency.
Diekman EF; Ferdinandusse S; van der Pol L; Waterham HR; Ruiter JP; Ijlst L; Wanders RJ; Houten SM; Wijburg FA; Blank AC; Asselbergs FW; Houtkooper RH; Visser G
Genet Med; 2015 Dec; 17(12):989-94. PubMed ID: 25834949
[TBL] [Abstract][Full Text] [Related]
4. Tissue-specific strategies of the very-long chain acyl-CoA dehydrogenase-deficient (VLCAD-/-) mouse to compensate a defective fatty acid β-oxidation.
Tucci S; Herebian D; Sturm M; Seibt A; Spiekerkoetter U
PLoS One; 2012; 7(9):e45429. PubMed ID: 23024820
[TBL] [Abstract][Full Text] [Related]
5. Proposal for an individualized dietary strategy in patients with very long-chain acyl-CoA dehydrogenase deficiency.
Bleeker JC; Kok IL; Ferdinandusse S; de Vries M; Derks TGJ; Mulder MF; Williams M; Gozalbo ER; Bosch AM; van den Hurk DT; de Sain-van der Velden MGM; Waterham HR; Wijburg FA; Visser G
J Inherit Metab Dis; 2019 Jan; 42(1):159-168. PubMed ID: 30740737
[TBL] [Abstract][Full Text] [Related]
6. Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency.
Diekman EF; Visser G; Schmitz JP; Nievelstein RA; de Sain-van der Velden M; Wardrop M; Van der Pol WL; Houten SM; van Riel NA; Takken T; Jeneson JA
PLoS One; 2016; 11(2):e0147818. PubMed ID: 26881790
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency.
Shiraishi H; Yamada K; Egawa K; Ishige M; Ochi F; Watanabe A; Kawakami S; Kuzume K; Watanabe K; Sameshima K; Nakamagoe K; Tamaoka A; Asahina N; Yokoshiki S; Kobayashi K; Miyakoshi T; Oba K; Isoe T; Hayashi H; Yamaguchi S; Sato N
Brain Dev; 2021 Feb; 43(2):214-219. PubMed ID: 32798077
[TBL] [Abstract][Full Text] [Related]
8. Molecular and cellular pathology of very-long-chain acyl-CoA dehydrogenase deficiency.
Schiff M; Mohsen AW; Karunanidhi A; McCracken E; Yeasted R; Vockley J
Mol Genet Metab; 2013 May; 109(1):21-7. PubMed ID: 23480858
[TBL] [Abstract][Full Text] [Related]
9. Cardiac tissue citric acid cycle intermediates in exercised very long-chain acyl-CoA dehydrogenase-deficient mice fed triheptanoin or medium-chain triglyceride.
Gaston G; Gangoiti JA; Winn S; Chan B; Barshop BA; Harding CO; Gillingham MB
J Inherit Metab Dis; 2020 Nov; 43(6):1232-1242. PubMed ID: 33448436
[TBL] [Abstract][Full Text] [Related]
10. The fate of medium-chain fatty acids in very long-chain acyl‑CoA dehydrogenase deficiency (VLCADD): A matter of sex?
Wehbe Z; Alatibi K; Jellusova J; Spiekerkoetter U; Tucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Nov; 1864(11):1591-1605. PubMed ID: 31394165
[TBL] [Abstract][Full Text] [Related]
11. Food withdrawal lowers energy expenditure and induces inactivity in long-chain fatty acid oxidation-deficient mouse models.
Diekman EF; van Weeghel M; Wanders RJ; Visser G; Houten SM
FASEB J; 2014 Jul; 28(7):2891-900. PubMed ID: 24648546
[TBL] [Abstract][Full Text] [Related]
12. Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era.
Janeiro P; Jotta R; Ramos R; Florindo C; Ventura FV; Vilarinho L; Tavares de Almeida I; Gaspar A
Eur J Pediatr; 2019 Mar; 178(3):387-394. PubMed ID: 30617651
[TBL] [Abstract][Full Text] [Related]
13. Development and pathomechanisms of cardiomyopathy in very long-chain acyl-CoA dehydrogenase deficient (VLCAD(-/-)) mice.
Tucci S; Flögel U; Hermann S; Sturm M; Schäfers M; Spiekerkoetter U
Biochim Biophys Acta; 2014 May; 1842(5):677-85. PubMed ID: 24530811
[TBL] [Abstract][Full Text] [Related]
14. Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?
Bastin J; Bonnefont JP; Djouadi F; Bresson JL
J Inherit Metab Dis; 2015 Mar; 38(2):371-2. PubMed ID: 25310995
[No Abstract] [Full Text] [Related]
15. De novo fatty acid biosynthesis and elongation in very long-chain acyl-CoA dehydrogenase-deficient mice supplemented with odd or even medium-chain fatty acids.
Tucci S; Behringer S; Spiekerkoetter U
FEBS J; 2015 Nov; 282(21):4242-53. PubMed ID: 26284828
[TBL] [Abstract][Full Text] [Related]
16. Muscle MRI in patients with long-chain fatty acid oxidation disorders.
Diekman EF; van der Pol WL; Nievelstein RA; Houten SM; Wijburg FA; Visser G
J Inherit Metab Dis; 2014 May; 37(3):405-13. PubMed ID: 24305961
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic challenge in very-long chain acyl-CoA dehydrogenase deficiency (VLCADD).
Hesse J; Braun C; Behringer S; Matysiak U; Spiekerkoetter U; Tucci S
J Inherit Metab Dis; 2018 Nov; 41(6):1169-1178. PubMed ID: 30194637
[TBL] [Abstract][Full Text] [Related]
18. Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes.
Bleeker JC; Kok IL; Ferdinandusse S; van der Pol WL; Cuppen I; Bosch AM; Langeveld M; Derks TGJ; Williams M; de Vries M; Mulder MF; Gozalbo ER; de Sain-van der Velden MGM; Rennings AJ; Schielen PJCI; Dekkers E; Houtkooper RH; Waterham HR; Pras-Raves ML; Wanders RJA; van Hasselt PM; Schoenmakers M; Wijburg FA; Visser G
J Inherit Metab Dis; 2019 May; 42(3):414-423. PubMed ID: 30761551
[TBL] [Abstract][Full Text] [Related]
19. Prolonged QT interval and lipid alterations beyond β-oxidation in very long-chain acyl-CoA dehydrogenase null mouse hearts.
Gélinas R; Thompson-Legault J; Bouchard B; Daneault C; Mansour A; Gillis MA; Charron G; Gavino V; Labarthe F; Des Rosiers C
Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H813-23. PubMed ID: 21685264
[TBL] [Abstract][Full Text] [Related]
20. AAV9 gene replacement therapy for respiratory insufficiency in very-long chain acyl-CoA dehydrogenase deficiency.
Zieger M; Keeler AM; Flotte TR; ElMallah MK
J Inherit Metab Dis; 2019 Sep; 42(5):870-877. PubMed ID: 30993714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
